Previous 10 | Next 10 |
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
Invitae loses money today but has the potential to monopolize the germline testing market. They use volume and COGS metrics to demonstrate the plausibility of their business model, but these measures don't tell the full story. Here are 7 challenges for their strategy. Until there ...
Small caps finally record a new high after two years and turn positive for the year. Vaccine progress is raising expectations of a more robust and durable economic recovery in 2021, driving a rotation into lagging segments and economically sensitive sectors. Small caps can witness...
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients -- Study finds nearly 1 in 10 show genetic changes with established clinical management recommendations, potential eligibility for precision therapies and/or clinical treatment trials -- --...
On November 15th, institutional investment managers with more than $100 million AUM had to disclosed their positions at the end of Q3 2020. Several stocks stand out when we look at the form 13F of some of the best-performing hedge funds. Focusing on the very best ideas, I reviewed...
Top line shows nice growth despite pandemic. Large losses still piling up and leading to massive cash burn. Outstanding share count has skyrocketed higher in 2020. For further details see: Invitae: Growth With Massive Dilution
Ark Investment Management's Innovation ETF invests in technologically enabled companies that have the potential for radical disruption. ARKK YTD is up 83.8% versus the S&P 500's 7.8%, which more than justifies the 0.75% expense ratio. In 2019, the fund’s portfolio turno...
PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, and Invitae (NYSE: NVTA), a leading medical genetics company, announce a collabo...
Image source: The Motley Fool. Invitae (NYSE: NVTA) Q3 2020 Earnings Call Nov 05, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Invitae (NVTA) Q3 2020 Earnings Call Transcript
The following slide deck was published by Invitae Corporation in conjunction with their 2020 Q3 earnings call. For further details see: Invitae Corporation 2020 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...